Salesforce Als-Con-201 Salesforce Certified Agentforce Life Sciences Consultant Exam Practice Test

Option A is correct because Salesforce Help for setting up the Inquiry record page for Medical Inquiries explicitly states that, to view timeline details for inquiries, the consultant should drag the Timeline component to the page. The requirement in the question is to expose a chronological list of key events and changes associated with the inquiry. That is exactly the purpose of the Timeline component on the Medical Inquiries record page.

Salesforce also documents Enhanced Timeline for Life Sciences Cloud, explaining that the Enhanced Timeline component shows key events relating to a person or a record. This supports the use case of giving users a consolidated, chronological view of relevant inquiry activity, rather than requiring them to inspect multiple related lists or audit records separately.

Option B is not the best answer because field history tracking and the standard History component are used for field-level audit history, not the Life Sciences Medical Inquiries timeline experience. Option C is also incorrect because adding an Inquiry History related list would expose related records, but it would not provide the configured timeline component experience described in Salesforce’s Medical Inquiries setup documentation.

Therefore, the consultant must drag the Timeline component onto the Lightning record page and configure its component details for the Inquiry record page.

Option C is correct because the issue occurs when an HCP joins a Remote Engagement call through an Experience Cloud site link. In this flow, the external HCP typically accesses the site as the Site Guest User, so the guest user needs the correct permission set to use the remote engagement experience. Salesforce Help for creating an Experience Cloud site for Remote Engagement states that admins must assign permission sets to the guest user of the site, including Access Remote Engagement for Digital Experience . This directly matches the error in the question: the HCP reaches the site, but receives an insufficient permissions error.

Option A is incorrect because the Life Sciences Commercial Admin permission set is intended for administrative users, not the Site Guest User serving an unauthenticated Remote Engagement portal. Assigning broad admin permissions to a guest user would also be inappropriate from a security and compliance perspective. Option B is also incorrect because the requirement is not to license the HCP as a Customer Community Plus user. The scenario describes an HCP joining from a link, and the Salesforce setup guidance specifically identifies a permission-set assignment for the Site Guest User.

Therefore, the consultant should assign the Access Remote Engagement for Digital Experience permission set to the Experience Cloud Site Guest User.

=========

Option B is correct because Salesforce Life Sciences Cloud Medical Insights uses Medical Insight and Medical Insight Account configuration to capture and surface qualitative observations from engagements. Salesforce Help states that admins configure Medical Insight and Medical Insight Account objects by customizing the record page layout and creating required field sets. This directly matches the requirement: MSLs need to record qualitative observations and make those insights visible in the related account and visit context.

Medical Insights are intended to record observations or insights from HCP engagements, while the related Medical Insight Account object supports association of those insights with relevant accounts. By configuring layouts and field sets, the consultant controls which insight fields are available to users and how the data appears in the Life Sciences user experience. This is a standard configuration approach rather than a custom development pattern.

Option A is incorrect because feed tracking supports collaboration and Chatter-style record-feed updates; it does not configure the Medical Insights data-entry and display model. Also, “Product Insight” is not the standard object referenced for this Life Sciences Medical Insights setup. Option C is incorrect because assessment task flows and Medical Inquiry metadata are separate capabilities. Medical Inquiries manage HCP questions and responses, while Medical Insights capture field observations. Therefore, the consultant should customize the Medical Insight page layout and create field sets on Medical Insight and Medical Insight Account objects.

=========

Option B is correct because Salesforce Life Sciences Cloud requires a specific API-name prefix for custom Lightning web components that should render as inline components in the Life Sciences mobile app. Salesforce Help for creating and adding an LWC as an inline component on a record page states that admins must create a custom mobile-ready LWC and add lscMobileInline_ as the prefix for the component’s API name. This exact prefix identifies the component as compatible with the Life Sciences mobile inline rendering framework.

This directly matches the issue in the scenario. The component exists and was added to the Account record page, but it does not render correctly as an inline component in the mobile app. The missing configuration is not the page placement itself, but the required naming convention that allows the Life Sciences mobile app to recognize and render the LWC inline.

Option A, lsc_mobile_, is incorrect because it is not the documented prefix for inline mobile LWCs. Option C, mobileInline_, is also incorrect because it omits the Life Sciences-specific lsc prefix and does not match the Salesforce Help requirement. Therefore, the consultant should rename or recreate the LWC API name using the lscMobileInline_ prefix so it functions correctly as an inline component in the Agentforce Life Sciences mobile app.

=========

Option C is correct because the requirement is strict enforcement. Salesforce Help for Sample Limit Template types states that when the enforcement type is Error, distributions are blocked after limits are met. This directly matches the legal requirement in the question: the field sales rep must be prevented from submitting the visit when the disbursement quantity exceeds the allowed limit.

A controlled substance requires a hard compliance stop rather than a soft business warning. Setting the Limit Enforcement Type to Error ensures that the rep receives an error message and must correct the sample quantity before continuing. This protects the company from noncompliant disbursements and supports controlled sampling governance.

Option A is incorrect because Warning is a soft-limit behavior. A warning may alert the rep that the limit has been exceeded, but it allows the rep to proceed. That does not meet the requirement to strictly prevent the transaction. Option B is also not the best answer because “Block” is not the documented Limit Enforcement Type in the sample-limit template options shown in Salesforce’s Life Sciences sample limit resources. The documented strict enforcement behavior is Error. Therefore, for controlled substances or any legally required hard stop, the consultant should configure the Sample Limit Template with Limit Enforcement Type set to Error.

Option A is correct because routines are the Life Sciences Cloud capability intended for reusable visit schedules and recurring route patterns. Salesforce Help describes Customer Engagement features as including the ability to optimize daily schedules by showing key events and applying predefined routines on the calendar. This directly matches the requirement: field sales reps repeatedly visit the same groups of accounts across weekly routes or multi-day coverage patterns and want to reuse those planned schedules instead of rebuilding visits every time.

Routines support practical field planning because a rep can save a predefined pattern of planned visits and apply it later when the same route or schedule is needed. This is different from simply grouping accounts.

Option B is not the best answer because account lists help reps organize, filter, and target groups of accounts, but they do not by themselves preserve a reusable multi-day visit schedule. Account lists can help with planning, but they are not the direct solution for saving and reapplying a planned route. Option C is also incorrect because Activity Plans define strategic goals, targets, and activity expectations across a period. They align engagement activity to business objectives, but they are not designed to save and reapply recurring visit schedules. Therefore, the consultant should recommend creating a routine that saves the predefined set of visits and applying that routine as needed.

The correct answer is A because Account Summarization can use different Cross-Object Field History Graph assignments by org or profile. Salesforce Help for Life Sciences Account Summarization states that administrators can create a Cross-Object Graph for Account Summarization and assign cross-object graphs to an org or profile. Salesforce also describes the Account Summarization workflow as using configured cross-object field history so summaries can include recent and relevant account changes from related objects.

In this case, KAMs see summaries that include Provider Visit and Medical Inquiry records, while field sales reps do not. Both groups have Read access to the objects, so object permission is not the root cause. The difference is most likely profile-based summarization configuration: the graph containing Provider Visit and Medical Inquiry data has been assigned to the KAM profile but not to the field sales rep profile.

Option B is incorrect because Account Summary generation in this scenario is driven by Cross-Object Field History Graph configuration, not membership in a Data 360 segment. Option C is also incorrect because the question explicitly says both user groups have Read access. View All is not the stated requirement for using a graph in summarization. Therefore, the issue is that the Cross-Object Field History Graph is not assigned to the field sales rep profile.

=========

The correct answer is A because the requirement is for a single embedded, interactive graph that visualizes multiple relationship types around an HCP. Salesforce describes Actionable Relationship Center (ARC) as a capability for viewing relationships among people and businesses in an interactive graph. Salesforce also describes ARC as supporting entity hierarchy and entity relationship visualization, and Life Sciences provider-card guidance references account-related object relationships in an ARC graph.

This scenario includes more than a simple parent-child hierarchy. The HCP has an employment relationship with one hospital, affiliation relationships with two additional hospitals, and a Key Opinion Leader role for a research study. ARC is designed for this type of multi-object, multi-relationship visualization. It allows users to see related entities in context and navigate through connected records from a graph-based interface rather than moving through several related lists.

Option B, Einstein Relationship Insights , is incorrect because it is not the Life Sciences page component used to display a configured relationship graph for HCP-related records. Option C, Account Hierarchy Visualization , is also too limited because account hierarchy is generally used for hierarchical account structures, not a broader relationship network involving employment, affiliations, KOL status, and research-study connections. Since the requirement calls for an interactive relationship graph embedded on the record page, the consultant should implement Actionable Relationship Center .

=========

The correct answer is B because the business requirement says the system must block additional distributions once the sample limit is met. In Salesforce Life Sciences sample management, sample limits are used to control how many samples can be distributed to HCPs based on rules such as product, time period, and visit limits. Salesforce Help describes sample management features as supporting efficient and compliant handling and distribution of drug samples, while sample limits are part of the setup used to govern sample distribution.

The distinction between enforcement types is important. A Warning allows the rep to continue after being alerted. A Threshold is typically used to identify when a limit is nearing or reaching a defined point, but it does not satisfy the requirement to prevent excess sample distribution. An Error is the strictest enforcement behavior because it stops the transaction when the configured limit would be exceeded.

Here, Cumulus Pharma needs hard compliance enforcement: maximum 5 units per HCP per calendar year and maximum 2 units per visit. Since the system must prevent field sales reps from exceeding those values, the consultant should set the sample limit enforcement type to Error . This ensures the disbursement cannot proceed when the annual or per-visit limit has already been reached.

=========

Option A is correct because the requirement is specifically to allow field sales reps to add colleagues as CC recipients when sending emails from the Life Sciences Cloud mobile app. Salesforce Help for customizing and sending emails in Life Sciences Cloud states that users can send emails from the Life Sciences Cloud mobile app from areas such as the home page, visit and account records, the content library, and the presentation player. The same Salesforce Help result also states that users can add colleagues as CC recipients, depending on the Salesforce admin’s configuration.

That wording directly matches the option “Add Colleagues as CC.” The purpose of the setting is not simply to expose a generic CC field, but to enable the Life Sciences mobile email experience where reps can copy internal colleagues on compliant business communications.

Option B, “Add CC Recipients,” is too generic and does not match the Life Sciences-specific setting name in the question. It describes the general email behavior but not the precise admin setting. Option C, “Enable CC Field Representative,” is also not correct because it implies a setting focused on copying the field representative, rather than allowing the field representative to add colleagues as CC recipients.

Therefore, to let field sales reps CC colleagues from the Agentforce Life Sciences mobile app, the consultant should enable Add Colleagues as CC.

=========

Option A is correct because Life Sciences Cloud Visit Management includes an Admin Console configuration called Map Visit Types to Accounts. This configuration is designed to associate the correct Visit record type with the relevant Account type. Salesforce Life Sciences setup resources reference Visit Management Admin Console tasks, including Configure Visit Settings, Activate Trigger Handlers, Schedule Visit Jobs, and Map Visit Types to Accounts. That mapping is the appropriate configuration when a company has separate visit processes for HCOs and HCPs.

In this scenario, Cumulus Pharma already has separate Account record types and separate Visit record types. The missing configuration is the relationship between those two sets of record types. Mapping Visit Types to Accounts ensures that, when a sales rep creates a visit from an HCO account, the HCO visit process is used, and when the rep creates a visit from an HCP account, the HCP visit process is used.

Option B is not the best answer because trigger handlers enable underlying Visit Management automation, but they do not define which Visit type is associated with each Account type. Option C is also incorrect because page layouts control what users see on record pages; they do not determine the visit process or Visit record type mapping. Therefore, the consultant should configure mappings in Map Visit Types to Accounts.

=========

Option A, HCP Remote Platform Conference, is correct. In Salesforce Life Sciences Cloud Remote Engagement, the consultant creates an Experience Cloud site so Healthcare Providers can join remote visits. Salesforce Help specifically states that the HCP Remote Platform Conference component is available under Custom Components and can also be found through the search bar when building the Experience Cloud page. This is the component that is placed on the page to support the remote engagement conference experience.

The question also mentions video playback and Terms & Conditions logic. Salesforce Life Sciences Cloud Remote Engagement setup includes configuration for video call settings and video call Terms and Conditions, and the Experience Cloud site component is the user-facing component that brings the HCP remote conference experience onto the page. Salesforce Help also references Remote Engagement setup tasks such as configuring video call settings with Twilio and configuring video call Terms and Conditions, showing that Twilio is part of the underlying video-call configuration rather than the Experience Cloud page component itself.

Option B, Twilio Connector, is incorrect because Twilio configuration supports the video service settings, but it is not the component dragged onto the Experience Cloud page canvas. Option C, Remote Video Player, is not the standard component name identified in the Salesforce setup documentation. Therefore, the out-of-the-box component the consultant should select is HCP Remote Platform Conference.

The correct answer is A because Salesforce Life Sciences Field Email allows field users to add colleagues as CC recipients. Salesforce Help for customizing and sending emails in Life Sciences Cloud states that users can send emails to healthcare professionals and healthcare organizations from their workflow, select an email template, and add colleagues as CC recipients.

This distinction matters for compliance. In Life Sciences engagement, HCPs and HCOs are the intended external recipients of approved email communications. The CC field is not intended as a free-form way to add additional HCPs. Instead, CC is used for internal collaboration or visibility, such as copying a colleague involved in the account, territory, or follow-up process. This helps keep HCP communications controlled, trackable, and aligned with approved email workflows.

Option B is incorrect because it suggests both HCPs and colleagues can be CC’d. Although emails are sent to HCPs or HCOs, Salesforce’s documented CC behavior specifically references colleagues as CC recipients. Option C is also incorrect because HCPs are the primary external recipients, not the users who should be copied in the CC field. Therefore, when sending email from the Agentforce Life Sciences mobile app, field sales reps can CC colleagues .

=========

Option C is correct because the requirement is to display a conditional indicator on the Provider Card based on the Targeted Account field. Salesforce Help states that Provider Cards consolidate account information from scattered objects and fields into a single interface. Salesforce also documents that, in the Provider Card template, admins can use data from Provider Account Territory Information, including the Targeted Account field, to show whether an account is a target account.

The correct pattern is to add an item group element to a section, include the Targeted Account field from the Provider Account Territory Info source object, and configure visibility conditions so the card shows the appropriate label. When the field value indicates that the account is targeted, the card can show “Target.” When it is not targeted, a separate condition can show “Not Target.”

Option A is not correct because applying record-level filters to show only targeted accounts would hide non-targeted accounts rather than displaying both “Target” and “Not Target” states. Option B is not the best answer because a repeater element is used for repeating sets of records; this requirement is a single account-level indicator. Therefore, item group elements with visibility conditions are the right configuration for the Provider Card indicator.

=========

The correct answer is B because the requirement is persona-specific. Cumulus Pharma does not want the two additional custom objects to influence provider summaries for all users; the new insights and market intelligence must be used only when the provider summary is generated for the Key Account Manager profile. Salesforce Life Sciences Account Summarization is designed to generate contextual provider summaries from the latest changes, interactions, and insights related to a healthcare provider, and its configuration includes profile-specific setup so different personas can receive summaries grounded in the information relevant to their role.

Creating mapping records in the Provider Summary Profile Mappings tab associates the relevant summary data with the KAM profile. This is the most precise configuration because it controls which profile receives access to the additional summary context. Option A is not the best answer because creating a cross-object graph and assigning it directly to a profile is not the described administrative mechanism for persona-based provider summary control. Option C is also too broad: updating the Provider Summary Objects mapping may make the custom objects available to the summarization framework, but the key requirement is limiting usage to the new KAM persona. Profile mapping is what ensures the new objects are applied only for that persona’s provider summary generation.

=========

Option B is correct because Salesforce Life Sciences Cloud provides a standard Data Change Requests framework for governed master-data updates. The requirement is not simply to block a change or create a manual task; it is to route critical HCP data changes to a Data Steward for review before the change is applied. Salesforce’s Life Sciences Cloud Account Management documentation describes Data Change Requests as a capability used to validate data changes by objects and fields and configure data changes by profile and record type. That aligns directly with controlled governance over fields such as Medical License Number.

The specific configuration object in the question, LifeSciDataChgPersonaDef, represents the persona-based data-change configuration. Salesforce’s Developer Guide identifies LifeSciDataChgPersonaDef as part of Data Change Requests and includes the ChangeUpdateType picklist field. Setting ChangeUpdateType to DoNotApplyChangesImmediately means changes are not applied directly by the sales rep persona and can instead be managed through the data-change governance process.

Option A is not the best answer because a custom record-triggered flow would duplicate standard Life Sciences Cloud data-change governance and could create maintenance or compliance risk. Option C is also not ideal because a validation rule only blocks the update; it does not create the governed change-request process needed for Data Steward review. Salesforce’s Data Change Requests data model includes Life Science Data Change Definition, managed fields, record types, persona definitions, and Life Science Data Change Request, confirming this is the intended standard architecture.

=========

Option C is correct because Salesforce Life Sciences Cloud supports manual territory alignment for affiliated accounts. Salesforce Help for Territory Alignment for Affiliated Accounts states that a user’s territory determines which accounts they can view and manage, and that users can manually align an affiliated account to their territory. The broader Affiliations documentation also explains that affiliation alignment rules can automatically align affiliated accounts, but the scenario specifically asks for manual alignment by field users when needed.

The correct Admin Console setting is therefore the one that enables users to align affiliated accounts to the user’s territory. This setting allows reps working with complex HCO/HCP affiliation networks to bring relevant affiliated accounts into their current territory alignment when the relationship is valid for their business process.

Option A is not the best answer because the requirement is not to align accounts outside the user’s territory. It is to let users align affiliated accounts to their own current territory. Option B is also incorrect because searching for accounts outside the user’s territory only affects discoverability. It does not grant the ability to perform the actual affiliated-account alignment. Therefore, the consultant should enable “Enable users to align affiliated accounts to the user’s territory” in Account Management > Affiliation.

Option B is correct because the requirement is based on an HCP’s affiliation with an HCO and a specialty filter. Salesforce Life Sciences Cloud supports Territory Alignment for Affiliated Accounts, which lets organizations align affiliated accounts to specific territories. Salesforce Help also states that admins can define affiliation alignment rules to automatically align affiliated accounts to territories. This is the correct configuration when territory assignment must depend on the relationship between an HCP and an HCO, rather than only the HCP’s standalone demographic or geographic attributes.

The question specifically says that only oncology-specialty HCPs affiliated with a specific HCO should be automatically aligned. An affiliation alignment rule can use Care Specialty as a criterion, so selecting “Oncology” ensures that only matching affiliated HCPs are included. Other specialties at the same HCO are excluded because they do not meet the specialty condition.

Option A is not the best answer because a territory geo assignment rule evaluates territory assignment using geographic or account-level criteria. It does not specifically model the affiliated-account relationship with the HCO. Option C is incorrect because sharing rules only control record visibility; they do not perform territory alignment. Therefore, the consultant should configure an affiliation alignment rule for the territory and select Care Specialty as “Oncology.”

=========

Option A is correct because Provider Activity Measure Type defines how engagement activities are measured and categorized in Activity Plans. Salesforce Help explains that an activity can be an interaction with a healthcare professional, such as a visit, and that a channel is the medium in which the interaction or activity occurs. This is exactly the requirement: Cumulus Pharma wants to distinguish email interactions from in-person visits so each channel can be counted separately against the field rep’s targets.

Salesforce Help for creating Activity Plans also states that admins should verify that a provider activity measure type has been created to track provider engagement activities. This confirms that Provider Activity Measure Type is the setup object used to define what kind of activity is being measured.

Option B, Provider Activity Goal, is not correct because it represents the target or goal assigned to providers or reps, such as six emails or three visits. It does not define the activity category itself. Option C, Provider Activity Plan Interaction, is also not the best answer because the question asks which configuration object defines the distinct interaction categories. The measure type is the categorization layer that can use Visit Channel, such as Email or In-Person, to count interactions separately. Therefore, Provider Activity Measure Type is the correct answer.

=========

The correct answer is B because off-label control in the visit experience is tied to product detailing behavior. In life sciences commercial engagement, product detailing governs what products, messages, indications, and approved content can be discussed or shown during a visit. Salesforce Trailhead describes Life Sciences Cloud content visibility as being filtered by territory, product assignment, and account restrictions to prevent off-label or noncompliant sharing. This aligns most closely with Visit Settings > Product Detailing Settings , because that is the visit configuration area where product discussion and detailing behavior is controlled.

The question asks where the consultant should configure whether reps are allowed to discuss products for unapproved indications. That is not a generic compliance switch; it is a visit-detailing control connected to product and indication behavior in the field engagement workflow. Product Detailing Settings are therefore the correct place to enforce whether off-label discussion is permitted, warned, or restricted according to company policy.

Option A is incorrect because “Compliance Settings > Off-Label Validation” is not the standard configuration path presented in the available options for the Life Sciences visit experience. Option C is also incorrect because Restricted Products would control whether products are available or restricted, but the scenario is specifically about discussion of unapproved indications during product detailing. Therefore, the consultant should use Visit Settings > Product Detailing Settings .

=========

Option B, Action Plan Template Assignment, is correct. In Salesforce Life Sciences Cloud Key Account Management, strategic planning uses goal definitions and action plan templates to standardize account-planning execution. A Goal Definition represents the reusable strategic goal blueprint, such as “Secure Formulary Access.” An Action Plan Template defines the repeatable tactical tasks that should be generated when that goal is added to an account plan. The object that connects these two pieces is ActionPlanTemplateAssignment. Salesforce’s Life Sciences Cloud Developer Guide describes ActionPlanTemplateAssignment as the object to which the action plan template is associated, including examples such as a problem definition, goal definition, or care plan template. This directly matches the scenario: the action plan template must be associated with the goal definition so that importing the predefined strategic goal can generate the related tactical action plan.

Option A is not correct because “Action Plan Template Goal” is not the standard object identified in the Salesforce Life Sciences Cloud data model for this association. Option C is also incorrect because an Action Plan Template Participant would relate to participants, not the relationship between a goal definition and an action plan template. Salesforce’s Key Account Management Account Plan data model also includes Action Plan Template Assignment, Action Plan Template, Action Plan Template Item, and Goal Definition as part of the standard account-planning architecture.

Therefore, the correct object for linking the tactical action plan template to the reusable strategic goal definition is Action Plan Template Assignment.

=========

The correct answer is C because the out-of-the-box Account Address batch job resolves duplicate primary Contact Point Address records by using the last modified record that is marked as primary . Salesforce Help for Life Sciences Account Address batch jobs states that if multiple Contact Point Address records are marked as primary, the job uses the last modified record marked as primary. This directly matches the scenario where the sales rep creates or updates another Contact Point Address and marks it as primary while the previous primary address remains unchanged.

Because both address records are now marked as primary, the batch job must determine which one should be treated as the effective primary address. Since the newly captured address was modified most recently and is marked as primary, the nightly Account Address batch job will use that last modified primary record. This behavior helps Life Sciences Cloud maintain a consistent primary-address reference when conflicting primary flags exist.

Option A is incorrect because the previous primary record is no longer the most recently modified primary record. The system does not automatically prefer the older record simply because it was primary first. Option B is incorrect because the newly captured record is not non-primary; the rep explicitly marked it as primary. The rule applies to records marked as primary, and among those records, the most recently modified one is selected. Therefore, the batch job will use the last modified record .

=========

Option B is correct because Presentation Page Product is the standard Life Sciences Cloud object that links presentation content to products. Salesforce’s Life Sciences Cloud Developer Guide states that PresentationPageProduct represents the link between a presentation page and a product, and may also include a connection to product guidance or product messages. This directly matches the requirement to link Immunexis to specific presentation pages or slide content so analytics can identify which products were detailed during visits.

Salesforce’s Intelligent Content data model also includes Presentation, Presentation Linked Page, Presentation Page, Presentation Page Product, Product2, Life Science Marketable Product, Provider Visit, and visit-detailing objects. This confirms that Presentation Page Product is part of the standard content and detailing analytics architecture for Life Sciences Customer Engagement.

Option A, Presentation Linked Page, is not the best answer because it links pages within presentation structure, but it does not specifically represent the product association. Option C, Product Media Link, is not the documented standard object for connecting Life Sciences presentation pages to products. Salesforce also provides a Presentation Page Product API resource for creating or updating product and guidance associations for a presentation page, reinforcing that this is the intended object.

Therefore, the consultant should use Presentation Page Product.

Option A, Provider Account Territory Summary, is the best answer because the requirement is to store summarized, territory-specific account metrics. The HCP belongs to more than one territory, and Cumulus Pharma must track Year-to-Date Visit Counts independently for each territory. Salesforce’s Life Sciences Account Management data model includes both Provider Account Territory Information and Provider Account Territory Summary as standard entities for managing healthcare provider and organization accounts, related profiles, and territory-specific information.

Provider Account Territory Summary is the object designed for summarized metrics at the provider-account-and-territory level. That makes it the appropriate place for values such as Year-to-Date Visit Counts, which are calculated or aggregated metrics rather than the raw alignment relationship itself.

Option C, Provider Account Territory Information, is related but not the best answer. Salesforce’s Developer Guide describes ProviderAcctTerritoryInfo as representing engagement data between an account and a user within an assigned territory, including items such as next provider visit date and preferred address. However, the question asks for territory-specific account metrics, not general engagement information between a user, account, and territory. Option B, Provider Account Territory Association, is also not correct because the issue is not simply associating an account to a territory. The HCP is already assigned to both territories. The need is to store independent summarized metrics for each territory. Therefore, Provider Account Territory Summary is the correct standard object.

=========

The correct answer is A from the available options, because the requirement is to control which user actions are exposed to different roles during the Medical Inquiry lifecycle. Salesforce Help for Medical Inquiries states that organizations can define relevant workflow actions for tasks users perform in the medical inquiry process, such as inquiry submission and assignment. Salesforce also describes a compliant role separation where field sales reps can submit medical inquiries, while Medical Science Liaisons can assign and respond to them.

The ideal Salesforce Life Sciences configuration pattern is to use Medical Inquiry workflow actions and workflow paths to control status transitions, actions, and permissions. However, among the provided answer choices, record types with role-specific page layouts is the only option that directly supports restricting the available buttons and actions by user role. This enables sales users to see only draft, sign, and submit actions, while MSL users see only assignment and response actions.

Option B is incorrect because a formula field can calculate or display logic, but it cannot enforce workflow actions or user interaction permissions by itself. Option C is also incorrect because a Flow action could add custom logic, but it is not the standard configuration approach for restricting Medical Inquiry lifecycle actions. Therefore, the best available answer is A .

=========

The correct answer is C because Salesforce Life Sciences Sample Inventory Management automatically adjusts the system count to match the actual count when an inventory-count discrepancy is recorded. Salesforce Help for Discrepancy Adjustments for Inventory Counts states that when a discrepancy is recorded in the inventory count, Sample Inventory Management adjusts the system count positively or negatively to match the actual count.

In this case, the physical count is 95 units, while the system balance is 100 units. The system must reflect the physical reality immediately for audit accuracy. Therefore, Life Sciences creates an adjustment transaction for the negative difference of 5 units so that the recorded inventory balance aligns with the counted quantity. This preserves the audit trail because the discrepancy is not silently overwritten; it is reconciled through an inventory adjustment transaction.

Option A is incorrect because a Product Request is used to request or replenish inventory, not to reconcile a counted discrepancy. The system should first record the loss or variance before any replenishment process is considered. Option B is also incorrect because locking the Product Item and triggering an assessment workflow is not the standard discrepancy reconciliation behavior described for inventory counts. The correct behavior is automatic generation of an adjustment transaction to reconcile the system balance with the physical count.

The correct answer is B because the standard field that represents whether a received document is incoming or outgoing is Direction . Salesforce’s Life Sciences Cloud Developer Guide for the ReceivedDocument object lists direction values such as INCOMING — Incoming and OUTGOING — Outgoing , which directly matches the reporting requirement in the scenario.

The operations manager wants to analyze document volume based on whether consent forms are flowing into the organization from HCPs or being sent out to HCPs. That is a directional reporting requirement, not a document lifecycle or status requirement. Grouping the report by the Direction field allows the team to separate inbound consent forms from outbound documents using standard Salesforce data rather than creating a custom field or relying on interpretation.

Option A, Flow Type , is incorrect because the question is not asking about a business process type, document-processing flow, or automation path. It specifically asks for whether the document was incoming or outgoing. Option C, Document Status , is also incorrect because status would indicate where the document is in its lifecycle, such as received, processed, pending, or completed depending on configuration. Status does not define the direction of the document exchange. Therefore, the consultant should recommend grouping and filtering the report by the standard Direction field on Received Document.

=========

Option C is correct because Advanced Sample Limit Templates are designed for custom, complex sample-limit rules. Salesforce Help explains that advanced sample limit templates are used to define custom sample limit rules for more complex needs and stricter requirements. This scenario requires two non-basic behaviors: a dynamic period start based on the product launch date and soft-limit enforcement that warns the rep but still allows the disbursement to proceed. Those requirements go beyond a generic calendar-year rule.

A Generic Sample Limit Template is not the best answer because generic templates are better suited for standard sample-limit logic. The requirement explicitly says the limit period must begin on the Product Launch Date rather than the standard Calendar Year, which makes the rule more specialized. A Country Sample Limit Template is also not correct because country templates are used for country-specific legal or regulatory sampling limits. In this question, the control is strategic and inventory-driven, not a legal requirement tied to a specific country.

Advanced templates are the correct fit because they allow more flexible configuration for business-specific sample controls, including nonstandard periods and warning-based enforcement. Therefore, the consultant should use an Advanced Sample Limit Template for the Immunexis launch sampling rule.

=========

Digital Verification is the correct answer because Salesforce Life Sciences resources describe it as the native capability used to manage electronic signatures in Salesforce and support an organization’s 21 CFR Part 11 compliance requirements. Salesforce Help states that Electronic Signatures can be set up using the Digital Verifications feature, allowing signatures to be managed in Salesforce instead of relying on a third-party application. It also references creating a “signature trail,” which is the key concept in this question: the signature is not just a stored image, but part of a controlled verification process tied to the signed record and signer context.

Field Audit Trail is not the best answer because it tracks field history and retention for data changes; it does not provide the electronic-signature process required for HCP sample acknowledgments. Adobe Sign is also not the best answer because the question asks for the Salesforce Life Sciences feature that generates the audit trail inside the Life Sciences process. The Salesforce Developer Guide also identifies Digital Verification standard objects as part of the electronic-signature data model, reinforcing that Digital Verification is the Life Sciences capability designed for this use case.

The correct answer is C because an Action Plan Template Assignment connects predefined action-plan tasks to reusable planning objectives so Key Account Managers can import standardized objectives into account plans with tactical steps already attached. Salesforce Help for Life Sciences Key Account Management explains that a Goal Definition represents a broad business objective that can be reused across global, national, and territory levels. It also states that when creating account plan objectives, users can import templates and choose goal definitions with action plans and assessment tasks to add to account plans.

The key phrase in the scenario is “with predefined tactical steps.” A high-level corporate objective alone would not be enough. The organization also wants repeatable execution tasks that KAMs can bring into individual account plans. Creating an Action Plan Template Assignment supports this by associating the action plan template with the goal definition, so the imported objective includes the structured actions needed for execution.

Option A, Account Plan Objective Link , is incorrect because it suggests linking an objective after the fact rather than defining a reusable objective with tactical steps. Option B, Goal Definition Product , is also not the best answer. A product association may be useful for a product launch, but it does not provide the predefined action-plan tasks required by the business process. Therefore, the consultant should create an Action Plan Template Assignment .

Option C is correct because the requirement is product-specific and should be configured through Product Discussion Settings, not through a generic page-layout or Visit validation rule. Salesforce’s Life Sciences Cloud Visit Management data model includes Provider Visit Product Discussion as the object that represents products discussed during a visit, including key details about the product brand, therapeutic area, and related information. Salesforce also documents ProviderVisitProdDiscussion as representing additional notes or information about products discussed during a healthcare provider visit.

The question asks for a configuration that applies when a specific product, such as Immunexis, is discussed. Enabling Require Discussion in Product Discussion Settings for the product record is the most targeted standard configuration because it ties the requirement to that product’s visit discussion behavior.

Option A is not the best answer because a custom validation rule on Visit would have to inspect related product-discussion records and could become complex or unreliable for mobile visit submission behavior. Option B is also insufficient because making a Comments field required on the page layout would apply based on the layout, not specifically when Immunexis is discussed. It also would not necessarily enforce product-specific discussion requirements across all relevant visit submission paths. Therefore, the consultant should enable Require Discussion in Product Discussion Settings for the Immunexis product record.

=========

Option A is correct because Life Sciences Workflow Management is designed to control what users can do at different stages of a Life Sciences process, including Medical Inquiries. Salesforce Help for configuring Life Sciences workflow paths states that admins define stage operation conditions that must be met to grant users access to operations. Salesforce also provides specific setup guidance for workflow stages used to manage Medical Inquiries, including adding actions to stage operations and configuring stage operation conditions.

This fits the requirement exactly. The access rules change depending on the Medical Inquiry’s stage: Draft, Assigned, Responded, Signed, or Submitted. Salesforce’s Inquiry object documentation confirms these inquiry statuses are standard values used in the Medical Inquiries process.

Option B is incorrect because criteria-based sharing rules on Case would not dynamically manage stage-specific CRUD behavior for the Life Sciences Inquiry workflow. Also, the question is about Medical Inquiries, not generic Case sharing. Option C is also incorrect because validation rules and dynamic page layouts can restrict or hide fields and actions, but they do not provide the standard stage-based security model required here. Therefore, the consultant should configure Stage Operations and Stage Operation Conditions within Life Sciences Workflow Management.

=========

Option B is correct because the requirement is specifically about making Consent Management data available in the Life Sciences mobile app. Salesforce Help for Consent Management states that admins must create object metadata cache configuration for supported Consent Management objects and generate a metadata cache so sales reps can view and update consent data. Salesforce also has a dedicated setup topic for creating Object Metadata Cache Configuration, which is accessed from the Life Sciences Commercial app Admin Console under Mobile.

This is important because the Life Sciences mobile app depends on generated metadata cache so that configured objects, fields, and layouts are available to field users on iPad and mobile workflows. Without the metadata cache for the Consent Management objects, reps may not be able to access or update consent preferences during visits, even if the consent model itself is configured correctly.

Option A is not the best answer because Subscription Filtering Fields help control filtering behavior for consent subscriptions, but they do not make the consent objects available in the mobile app. Option C is also incorrect because configuring a desktop Lightning record page does not satisfy the Life Sciences mobile app metadata requirement. Therefore, the consultant should create the object metadata cache configuration for Consent Management objects and generate the metadata cache.

=========

Data Use Purpose is the correct answer. In Salesforce Life Sciences Cloud Consent Management, a Communication Subscription represents a specific subscription, such as a newsletter, and the consent model must also connect that subscription to the business purpose and relevant Life Sciences product. Salesforce’s Life Sciences Help documentation specifically describes creating a Data Use Purpose record to associate a Life Sciences Marketable Product with a Communication Subscription. That directly matches the scenario: “Immunology Monthly” is the Communication Subscription, and “Immunexis” is the product record that must be linked for consent capture.

Engagement Channel Type is not correct because it represents the channel through which the HCP can be contacted, such as email, SMS, or other communication methods. It defines the communication channel, not the relationship between a subscription and a marketable product. Communication Subscription Consent is also not correct because it represents an individual customer’s or HCP’s consent preference for a subscription. In other words, that record is created or updated when the HCP opts in or opts out; it is not the setup record used to link the newsletter subscription to the product. Salesforce’s Life Sciences standard object documentation also describes Communication Subscription Consent as representing a customer’s consent to a communication subscription, reinforcing that it stores the HCP’s consent outcome rather than the product-subscription configuration.

=========

The correct answer is A because the subscription and channel must be connected before reps can capture consent for that channel. Salesforce’s Life Sciences Consent Management model includes Communication Subscription , Engagement Channel Type , and Communication Subscription Channel Type as standard entities for capturing and managing HCP consent and communication preferences. The Communication Subscription Channel Type object acts as the junction between a subscription topic, such as “Immunexis KOL Webinar Series,” and a channel, such as Email.

In the scenario, the subscription is visible, which confirms that the Communication Subscription record exists and is available in the mobile consent experience. However, Email is not selectable because the subscription has not been associated with the Email engagement channel. Creating the Communication Subscription Channel Type record resolves this gap by telling the system that this subscription can be consented to through the Email channel.

Option B is incorrect because Communication Subscription Consent records represent an individual HCP’s consent decision, such as opt-in or opt-out. They do not control whether a channel is available for a subscription. The channel must first be configured as valid for the subscription. After that, reps can capture the HCP’s opt-in preference during the visit. Therefore, the consultant should create the Communication Subscription Channel Type junction record.

=========

The correct answer is B because the requirement is product-specific consent tracking. Salesforce’s Life Sciences Consent Management data model is designed for capturing and managing HCP consent and communication preferences. The model includes objects such as Communication Subscription , Communication Subscription Consent , Contact Point Consent , and Life Science Marketable Product , which together support consent management across communication channels and products.

When a field sales rep captures whether an HCP agrees to receive communications for a specific product, the consent must be tied both to the communication/contact point consent and to the relevant Life Sciences Marketable Product. A Life Sciences Marketable Product Consent record provides that product-level association, allowing the organization to track consent preferences for a particular product rather than only a general channel or subscription.

Option A is incorrect because Data Use Purpose represents the purpose for using data, such as marketing or communication, but it does not by itself create a product-specific consent relationship between an HCP’s contact point and a marketable product. Option C is also incorrect because adding a custom lookup to Communication Subscription Consent would be unnecessary and less aligned with the standard Life Sciences consent model. The best-practice configuration is to use the standard product-consent relationship by creating a Life Sciences Marketable Product Consent record linked to the relevant Contact Point Consent and product.